1 Market Overview

1.1 Product Overview and Scope of Tumor Immunotherapy

1.2 Classification of Tumor Immunotherapy by Type

1.2.1 Overview: Global Tumor Immunotherapy Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Tumor Immunotherapy Revenue Market Share by Type in 2021

1.2.3 Tumor Infiltrating Lymphocyte (TIL) Treatment

1.2.4 Engineered T Cell Receptor (TCR) Therapy

1.2.5 Chimeric Antigen Receptor (CAR) T Cell Therapy

1.2.6 Natural Killer (NK) Cell Therapy

1.2.7 Other

1.3 Global Tumor Immunotherapy Market by Application

1.3.1 Overview: Global Tumor Immunotherapy Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Biopharmaceutical Company

1.3.3 Hospital

1.3.4 Universities And Other Scientific Research Institutions

1.3.5 Other

1.4 Global Tumor Immunotherapy Market Size & Forecast

1.5 Global Tumor Immunotherapy Market Size and Forecast by Region

1.5.1 Global Tumor Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Tumor Immunotherapy Market Size by Region, (2017-2022)

1.5.3 North America Tumor Immunotherapy Market Size and Prospect (2017-2028)

1.5.4 Europe Tumor Immunotherapy Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Tumor Immunotherapy Market Size and Prospect (2017-2028)

1.5.6 South America Tumor Immunotherapy Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Tumor Immunotherapy Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Tumor Immunotherapy Market Drivers

1.6.2 Tumor Immunotherapy Market Restraints

1.6.3 Tumor Immunotherapy Trends Analysis

2 Company Profiles

2.1 Roche

2.1.1 Roche Details

2.1.2 Roche Major Business

2.1.3 Roche Tumor Immunotherapy Product and Solutions

2.1.4 Roche Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Roche Recent Developments and Future Plans

2.2 Merck

2.2.1 Merck Details

2.2.2 Merck Major Business

2.2.3 Merck Tumor Immunotherapy Product and Solutions

2.2.4 Merck Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Merck Recent Developments and Future Plans

2.3 Novartis

2.3.1 Novartis Details

2.3.2 Novartis Major Business

2.3.3 Novartis Tumor Immunotherapy Product and Solutions

2.3.4 Novartis Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Novartis Recent Developments and Future Plans

2.4 Johnson & Johnson

2.4.1 Johnson & Johnson Details

2.4.2 Johnson & Johnson Major Business

2.4.3 Johnson & Johnson Tumor Immunotherapy Product and Solutions

2.4.4 Johnson & Johnson Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Johnson & Johnson Recent Developments and Future Plans

2.5 GlaxoSmithKline

2.5.1 GlaxoSmithKline Details

2.5.2 GlaxoSmithKline Major Business

2.5.3 GlaxoSmithKline Tumor Immunotherapy Product and Solutions

2.5.4 GlaxoSmithKline Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 GlaxoSmithKline Recent Developments and Future Plans

2.6 AbbVie

2.6.1 AbbVie Details

2.6.2 AbbVie Major Business

2.6.3 AbbVie Tumor Immunotherapy Product and Solutions

2.6.4 AbbVie Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 AbbVie Recent Developments and Future Plans

2.7 ELI Lilly

2.7.1 ELI Lilly Details

2.7.2 ELI Lilly Major Business

2.7.3 ELI Lilly Tumor Immunotherapy Product and Solutions

2.7.4 ELI Lilly Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 ELI Lilly Recent Developments and Future Plans

2.8 Amgen

2.8.1 Amgen Details

2.8.2 Amgen Major Business

2.8.3 Amgen Tumor Immunotherapy Product and Solutions

2.8.4 Amgen Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Amgen Recent Developments and Future Plans

2.9 AstraZeneca

2.9.1 AstraZeneca Details

2.9.2 AstraZeneca Major Business

2.9.3 AstraZeneca Tumor Immunotherapy Product and Solutions

2.9.4 AstraZeneca Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 AstraZeneca Recent Developments and Future Plans

2.10 Bristol-Mysers Squibb

2.10.1 Bristol-Mysers Squibb Details

2.10.2 Bristol-Mysers Squibb Major Business

2.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Product and Solutions

2.10.4 Bristol-Mysers Squibb Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Bristol-Mysers Squibb Recent Developments and Future Plans

2.11 Kite Pharma

2.11.1 Kite Pharma Details

2.11.2 Kite Pharma Major Business

2.11.3 Kite Pharma Tumor Immunotherapy Product and Solutions

2.11.4 Kite Pharma Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Kite Pharma Recent Developments and Future Plans

2.12 Adaptimmune

2.12.1 Adaptimmune Details

2.12.2 Adaptimmune Major Business

2.12.3 Adaptimmune Tumor Immunotherapy Product and Solutions

2.12.4 Adaptimmune Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Adaptimmune Recent Developments and Future Plans

2.13 Altor Bioscience Corporation

2.13.1 Altor Bioscience Corporation Details

2.13.2 Altor Bioscience Corporation Major Business

2.13.3 Altor Bioscience Corporation Tumor Immunotherapy Product and Solutions

2.13.4 Altor Bioscience Corporation Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Altor Bioscience Corporation Recent Developments and Future Plans

2.14 Cellectis

2.14.1 Cellectis Details

2.14.2 Cellectis Major Business

2.14.3 Cellectis Tumor Immunotherapy Product and Solutions

2.14.4 Cellectis Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Cellectis Recent Developments and Future Plans

2.15 Juno Therapeutics

2.15.1 Juno Therapeutics Details

2.15.2 Juno Therapeutics Major Business

2.15.3 Juno Therapeutics Tumor Immunotherapy Product and Solutions

2.15.4 Juno Therapeutics Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Juno Therapeutics Recent Developments and Future Plans

2.16 Takara Bio

2.16.1 Takara Bio Details

2.16.2 Takara Bio Major Business

2.16.3 Takara Bio Tumor Immunotherapy Product and Solutions

2.16.4 Takara Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Takara Bio Recent Developments and Future Plans

2.17 Unum Therapeutics

2.17.1 Unum Therapeutics Details

2.17.2 Unum Therapeutics Major Business

2.17.3 Unum Therapeutics Tumor Immunotherapy Product and Solutions

2.17.4 Unum Therapeutics Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17.5 Unum Therapeutics Recent Developments and Future Plans

2.18 Sunway

2.18.1 Sunway Details

2.18.2 Sunway Major Business

2.18.3 Sunway Tumor Immunotherapy Product and Solutions

2.18.4 Sunway Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.18.5 Sunway Recent Developments and Future Plans

2.19 Junshi Bio

2.19.1 Junshi Bio Details

2.19.2 Junshi Bio Major Business

2.19.3 Junshi Bio Tumor Immunotherapy Product and Solutions

2.19.4 Junshi Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.19.5 Junshi Bio Recent Developments and Future Plans

2.20 Cinda Bio

2.20.1 Cinda Bio Details

2.20.2 Cinda Bio Major Business

2.20.3 Cinda Bio Tumor Immunotherapy Product and Solutions

2.20.4 Cinda Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.20.5 Cinda Bio Recent Developments and Future Plans

2.21 BeiGene

2.21.1 BeiGene Details

2.21.2 BeiGene Major Business

2.21.3 BeiGene Tumor Immunotherapy Product and Solutions

2.21.4 BeiGene Tumor Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.21.5 BeiGene Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Tumor Immunotherapy Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Tumor Immunotherapy Players Market Share in 2021

3.2.2 Top 10 Tumor Immunotherapy Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Tumor Immunotherapy Players Head Office, Products and Services Provided

3.4 Tumor Immunotherapy Mergers & Acquisitions

3.5 Tumor Immunotherapy New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Tumor Immunotherapy Revenue and Market Share by Type (2017-2022)

4.2 Global Tumor Immunotherapy Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Tumor Immunotherapy Revenue Market Share by Application (2017-2022)

5.2 Global Tumor Immunotherapy Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Tumor Immunotherapy Revenue by Type (2017-2028)

6.2 North America Tumor Immunotherapy Revenue by Application (2017-2028)

6.3 North America Tumor Immunotherapy Market Size by Country

6.3.1 North America Tumor Immunotherapy Revenue by Country (2017-2028)

6.3.2 United States Tumor Immunotherapy Market Size and Forecast (2017-2028)

6.3.3 Canada Tumor Immunotherapy Market Size and Forecast (2017-2028)

6.3.4 Mexico Tumor Immunotherapy Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Tumor Immunotherapy Revenue by Type (2017-2028)

7.2 Europe Tumor Immunotherapy Revenue by Application (2017-2028)

7.3 Europe Tumor Immunotherapy Market Size by Country

7.3.1 Europe Tumor Immunotherapy Revenue by Country (2017-2028)

7.3.2 Germany Tumor Immunotherapy Market Size and Forecast (2017-2028)

7.3.3 France Tumor Immunotherapy Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Tumor Immunotherapy Market Size and Forecast (2017-2028)

7.3.5 Russia Tumor Immunotherapy Market Size and Forecast (2017-2028)

7.3.6 Italy Tumor Immunotherapy Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Tumor Immunotherapy Revenue by Type (2017-2028)

8.2 Asia-Pacific Tumor Immunotherapy Revenue by Application (2017-2028)

8.3 Asia-Pacific Tumor Immunotherapy Market Size by Region

8.3.1 Asia-Pacific Tumor Immunotherapy Revenue by Region (2017-2028)

8.3.2 China Tumor Immunotherapy Market Size and Forecast (2017-2028)

8.3.3 Japan Tumor Immunotherapy Market Size and Forecast (2017-2028)

8.3.4 South Korea Tumor Immunotherapy Market Size and Forecast (2017-2028)

8.3.5 India Tumor Immunotherapy Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Tumor Immunotherapy Market Size and Forecast (2017-2028)

8.3.7 Australia Tumor Immunotherapy Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Tumor Immunotherapy Revenue by Type (2017-2028)

9.2 South America Tumor Immunotherapy Revenue by Application (2017-2028)

9.3 South America Tumor Immunotherapy Market Size by Country

9.3.1 South America Tumor Immunotherapy Revenue by Country (2017-2028)

9.3.2 Brazil Tumor Immunotherapy Market Size and Forecast (2017-2028)

9.3.3 Argentina Tumor Immunotherapy Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Tumor Immunotherapy Revenue by Type (2017-2028)

10.2 Middle East & Africa Tumor Immunotherapy Revenue by Application (2017-2028)

10.3 Middle East & Africa Tumor Immunotherapy Market Size by Country

10.3.1 Middle East & Africa Tumor Immunotherapy Revenue by Country (2017-2028)

10.3.2 Turkey Tumor Immunotherapy Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Tumor Immunotherapy Market Size and Forecast (2017-2028)

10.3.4 UAE Tumor Immunotherapy Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Tumor Immunotherapy Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Tumor Immunotherapy Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Tumor Immunotherapy Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Tumor Immunotherapy Revenue (USD Million) by Region (2017-2022)

Table 5. Global Tumor Immunotherapy Revenue Market Share by Region (2023-2028)

Table 6. Roche Corporate Information, Head Office, and Major Competitors

Table 7. Roche Major Business

Table 8. Roche Tumor Immunotherapy Product and Solutions

Table 9. Roche Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Merck Corporate Information, Head Office, and Major Competitors

Table 11. Merck Major Business

Table 12. Merck Tumor Immunotherapy Product and Solutions

Table 13. Merck Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Novartis Corporate Information, Head Office, and Major Competitors

Table 15. Novartis Major Business

Table 16. Novartis Tumor Immunotherapy Product and Solutions

Table 17. Novartis Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Johnson & Johnson Corporate Information, Head Office, and Major Competitors

Table 19. Johnson & Johnson Major Business

Table 20. Johnson & Johnson Tumor Immunotherapy Product and Solutions

Table 21. Johnson & Johnson Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors

Table 23. GlaxoSmithKline Major Business

Table 24. GlaxoSmithKline Tumor Immunotherapy Product and Solutions

Table 25. GlaxoSmithKline Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. AbbVie Corporate Information, Head Office, and Major Competitors

Table 27. AbbVie Major Business

Table 28. AbbVie Tumor Immunotherapy Product and Solutions

Table 29. AbbVie Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. ELI Lilly Corporate Information, Head Office, and Major Competitors

Table 31. ELI Lilly Major Business

Table 32. ELI Lilly Tumor Immunotherapy Product and Solutions

Table 33. ELI Lilly Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Amgen Corporate Information, Head Office, and Major Competitors

Table 35. Amgen Major Business

Table 36. Amgen Tumor Immunotherapy Product and Solutions

Table 37. Amgen Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 39. AstraZeneca Major Business

Table 40. AstraZeneca Tumor Immunotherapy Product and Solutions

Table 41. AstraZeneca Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Bristol-Mysers Squibb Corporate Information, Head Office, and Major Competitors

Table 43. Bristol-Mysers Squibb Major Business

Table 44. Bristol-Mysers Squibb Tumor Immunotherapy Product and Solutions

Table 45. Bristol-Mysers Squibb Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Kite Pharma Corporate Information, Head Office, and Major Competitors

Table 47. Kite Pharma Major Business

Table 48. Kite Pharma Tumor Immunotherapy Product and Solutions

Table 49. Kite Pharma Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Adaptimmune Corporate Information, Head Office, and Major Competitors

Table 51. Adaptimmune Major Business

Table 52. Adaptimmune Tumor Immunotherapy Product and Solutions

Table 53. Adaptimmune Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Altor Bioscience Corporation Corporate Information, Head Office, and Major Competitors

Table 55. Altor Bioscience Corporation Major Business

Table 56. Altor Bioscience Corporation Tumor Immunotherapy Product and Solutions

Table 57. Altor Bioscience Corporation Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Cellectis Corporate Information, Head Office, and Major Competitors

Table 59. Cellectis Major Business

Table 60. Cellectis Tumor Immunotherapy Product and Solutions

Table 61. Cellectis Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Juno Therapeutics Corporate Information, Head Office, and Major Competitors

Table 63. Juno Therapeutics Major Business

Table 64. Juno Therapeutics Tumor Immunotherapy Product and Solutions

Table 65. Juno Therapeutics Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Takara Bio Corporate Information, Head Office, and Major Competitors

Table 67. Takara Bio Major Business

Table 68. Takara Bio Tumor Immunotherapy Product and Solutions

Table 69. Takara Bio Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. Unum Therapeutics Corporate Information, Head Office, and Major Competitors

Table 71. Unum Therapeutics Major Business

Table 72. Unum Therapeutics Tumor Immunotherapy Product and Solutions

Table 73. Unum Therapeutics Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 74. Sunway Corporate Information, Head Office, and Major Competitors

Table 75. Sunway Major Business

Table 76. Sunway Tumor Immunotherapy Product and Solutions

Table 77. Sunway Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 78. Junshi Bio Corporate Information, Head Office, and Major Competitors

Table 79. Junshi Bio Major Business

Table 80. Junshi Bio Tumor Immunotherapy Product and Solutions

Table 81. Junshi Bio Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 82. Cinda Bio Corporate Information, Head Office, and Major Competitors

Table 83. Cinda Bio Major Business

Table 84. Cinda Bio Tumor Immunotherapy Product and Solutions

Table 85. Cinda Bio Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 86. BeiGene Corporate Information, Head Office, and Major Competitors

Table 87. BeiGene Major Business

Table 88. BeiGene Tumor Immunotherapy Product and Solutions

Table 89. BeiGene Tumor Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 90. Global Tumor Immunotherapy Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 91. Global Tumor Immunotherapy Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 92. Breakdown of Tumor Immunotherapy by Company Type (Tier 1, Tier 2 and Tier 3)

Table 93. Tumor Immunotherapy Players Head Office, Products and Services Provided

Table 94. Tumor Immunotherapy Mergers & Acquisitions in the Past Five Years

Table 95. Tumor Immunotherapy New Entrants and Expansion Plans

Table 96. Global Tumor Immunotherapy Revenue (USD Million) by Type (2017-2022)

Table 97. Global Tumor Immunotherapy Revenue Share by Type (2017-2022)

Table 98. Global Tumor Immunotherapy Revenue Forecast by Type (2023-2028)

Table 99. Global Tumor Immunotherapy Revenue by Application (2017-2022)

Table 100. Global Tumor Immunotherapy Revenue Forecast by Application (2023-2028)

Table 101. North America Tumor Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 102. North America Tumor Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 103. North America Tumor Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 104. North America Tumor Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 105. North America Tumor Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 106. North America Tumor Immunotherapy Revenue by Country (2023-2028) & (USD Million)

Table 107. Europe Tumor Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 108. Europe Tumor Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 109. Europe Tumor Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 110. Europe Tumor Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 111. Europe Tumor Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 112. Europe Tumor Immunotherapy Revenue by Country (2023-2028) & (USD Million)

Table 113. Asia-Pacific Tumor Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 114. Asia-Pacific Tumor Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 115. Asia-Pacific Tumor Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 116. Asia-Pacific Tumor Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 117. Asia-Pacific Tumor Immunotherapy Revenue by Region (2017-2022) & (USD Million)

Table 118. Asia-Pacific Tumor Immunotherapy Revenue by Region (2023-2028) & (USD Million)

Table 119. South America Tumor Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 120. South America Tumor Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 121. South America Tumor Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 122. South America Tumor Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 123. South America Tumor Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 124. South America Tumor Immunotherapy Revenue by Country (2023-2028) & (USD Million)

Table 125. Middle East & Africa Tumor Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 126. Middle East & Africa Tumor Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 127. Middle East & Africa Tumor Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 128. Middle East & Africa Tumor Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 129. Middle East & Africa Tumor Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 130. Middle East & Africa Tumor Immunotherapy Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Tumor Immunotherapy Picture

Figure 2. Global Tumor Immunotherapy Revenue Market Share by Type in 2021

Figure 3. Tumor Infiltrating Lymphocyte (TIL) Treatment

Figure 4. Engineered T Cell Receptor (TCR) Therapy

Figure 5. Chimeric Antigen Receptor (CAR) T Cell Therapy

Figure 6. Natural Killer (NK) Cell Therapy

Figure 7. Other

Figure 8. Tumor Immunotherapy Revenue Market Share by Application in 2021

Figure 9. Biopharmaceutical Company Picture

Figure 10. Hospital Picture

Figure 11. Universities And Other Scientific Research Institutions Picture

Figure 12. Other Picture

Figure 13. Global Tumor Immunotherapy Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 14. Global Tumor Immunotherapy Revenue and Forecast (2017-2028) & (USD Million)

Figure 15. Global Tumor Immunotherapy Revenue Market Share by Region (2017-2028)

Figure 16. Global Tumor Immunotherapy Revenue Market Share by Region in 2021

Figure 17. North America Tumor Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Europe Tumor Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Asia-Pacific Tumor Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. South America Tumor Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Middle East and Africa Tumor Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 22. Tumor Immunotherapy Market Drivers

Figure 23. Tumor Immunotherapy Market Restraints

Figure 24. Tumor Immunotherapy Market Trends

Figure 25. Roche Recent Developments and Future Plans

Figure 26. Merck Recent Developments and Future Plans

Figure 27. Novartis Recent Developments and Future Plans

Figure 28. Johnson & Johnson Recent Developments and Future Plans

Figure 29. GlaxoSmithKline Recent Developments and Future Plans

Figure 30. AbbVie Recent Developments and Future Plans

Figure 31. ELI Lilly Recent Developments and Future Plans

Figure 32. Amgen Recent Developments and Future Plans

Figure 33. AstraZeneca Recent Developments and Future Plans

Figure 34. Bristol-Mysers Squibb Recent Developments and Future Plans

Figure 35. Kite Pharma Recent Developments and Future Plans

Figure 36. Adaptimmune Recent Developments and Future Plans

Figure 37. Altor Bioscience Corporation Recent Developments and Future Plans

Figure 38. Cellectis Recent Developments and Future Plans

Figure 39. Juno Therapeutics Recent Developments and Future Plans

Figure 40. Takara Bio Recent Developments and Future Plans

Figure 41. Unum Therapeutics Recent Developments and Future Plans

Figure 42. Sunway Recent Developments and Future Plans

Figure 43. Junshi Bio Recent Developments and Future Plans

Figure 44. Cinda Bio Recent Developments and Future Plans

Figure 45. BeiGene Recent Developments and Future Plans

Figure 46. Global Tumor Immunotherapy Revenue Share by Players in 2021

Figure 47. Tumor Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 48. Global Top 3 Players Tumor Immunotherapy Revenue Market Share in 2021

Figure 49. Global Top 10 Players Tumor Immunotherapy Revenue Market Share in 2021

Figure 50. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 51. Global Tumor Immunotherapy Revenue Share by Type in 2021

Figure 52. Global Tumor Immunotherapy Market Share Forecast by Type (2023-2028)

Figure 53. Global Tumor Immunotherapy Revenue Share by Application in 2021

Figure 54. Global Tumor Immunotherapy Market Share Forecast by Application (2023-2028)

Figure 55. North America Tumor Immunotherapy Sales Market Share by Type (2017-2028)

Figure 56. North America Tumor Immunotherapy Sales Market Share by Application (2017-2028)

Figure 57. North America Tumor Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 58. United States Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Canada Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Mexico Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Europe Tumor Immunotherapy Sales Market Share by Type (2017-2028)

Figure 62. Europe Tumor Immunotherapy Sales Market Share by Application (2017-2028)

Figure 63. Europe Tumor Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 64. Germany Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. France Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. United Kingdom Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Russia Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Italy Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Asia-Pacific Tumor Immunotherapy Sales Market Share by Type (2017-2028)

Figure 70. Asia-Pacific Tumor Immunotherapy Sales Market Share by Application (2017-2028)

Figure 71. Asia-Pacific Tumor Immunotherapy Revenue Market Share by Region (2017-2028)

Figure 72. China Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. Japan Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. South Korea Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. India Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Southeast Asia Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Australia Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. South America Tumor Immunotherapy Sales Market Share by Type (2017-2028)

Figure 79. South America Tumor Immunotherapy Sales Market Share by Application (2017-2028)

Figure 80. South America Tumor Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 81. Brazil Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. Argentina Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 83. Middle East and Africa Tumor Immunotherapy Sales Market Share by Type (2017-2028)

Figure 84. Middle East and Africa Tumor Immunotherapy Sales Market Share by Application (2017-2028)

Figure 85. Middle East and Africa Tumor Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 86. Turkey Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 87. Saudi Arabia Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 88. UAE Tumor Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 89. Methodology

Figure 90. Research Process and Data Source